| Product Code: ETC7650100 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Israel Dopamine Agonist Drug Market Overview |
3.1 Israel Country Macro Economic Indicators |
3.2 Israel Dopamine Agonist Drug Market Revenues & Volume, 2021 & 2031F |
3.3 Israel Dopamine Agonist Drug Market - Industry Life Cycle |
3.4 Israel Dopamine Agonist Drug Market - Porter's Five Forces |
3.5 Israel Dopamine Agonist Drug Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Israel Dopamine Agonist Drug Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.7 Israel Dopamine Agonist Drug Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.8 Israel Dopamine Agonist Drug Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.9 Israel Dopamine Agonist Drug Market Revenues & Volume Share, By End- Users, 2021 & 2031F |
3.10 Israel Dopamine Agonist Drug Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Israel Dopamine Agonist Drug Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of neurological disorders in Israel |
4.2.2 Rising awareness about the benefits of dopamine agonist drugs |
4.2.3 Growing investments in healthcare infrastructure and research development in Israel |
4.3 Market Restraints |
4.3.1 Stringent regulations and approval processes for new drugs in Israel |
4.3.2 High costs associated with the development and manufacturing of dopamine agonist drugs |
5 Israel Dopamine Agonist Drug Market Trends |
6 Israel Dopamine Agonist Drug Market, By Types |
6.1 Israel Dopamine Agonist Drug Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Israel Dopamine Agonist Drug Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 Israel Dopamine Agonist Drug Market Revenues & Volume, By Non-Ergoline Dopamine Agonists, 2021- 2031F |
6.1.4 Israel Dopamine Agonist Drug Market Revenues & Volume, By Ergot-Derived Dopamine Agonists, 2021- 2031F |
6.1.5 Israel Dopamine Agonist Drug Market Revenues & Volume, By Recombinant Factor VIII, 2021- 2031F |
6.1.6 Israel Dopamine Agonist Drug Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Israel Dopamine Agonist Drug Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 Israel Dopamine Agonist Drug Market Revenues & Volume, By Parkinson's Disease, 2021- 2031F |
6.2.3 Israel Dopamine Agonist Drug Market Revenues & Volume, By Restless Leg Syndrome, 2021- 2031F |
6.2.4 Israel Dopamine Agonist Drug Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Israel Dopamine Agonist Drug Market, By Drugs |
6.3.1 Overview and Analysis |
6.3.2 Israel Dopamine Agonist Drug Market Revenues & Volume, By Carbidopa and Levodopa, 2021- 2031F |
6.3.3 Israel Dopamine Agonist Drug Market Revenues & Volume, By Ropinirole, 2021- 2031F |
6.3.4 Israel Dopamine Agonist Drug Market Revenues & Volume, By Pramipexole, 2021- 2031F |
6.3.5 Israel Dopamine Agonist Drug Market Revenues & Volume, By Cabergoline, 2021- 2031F |
6.3.6 Israel Dopamine Agonist Drug Market Revenues & Volume, By Bromocriptine, 2021- 2031F |
6.3.7 Israel Dopamine Agonist Drug Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Israel Dopamine Agonist Drug Market, By Route of Administration |
6.4.1 Overview and Analysis |
6.4.2 Israel Dopamine Agonist Drug Market Revenues & Volume, By Oral, 2021- 2031F |
6.4.3 Israel Dopamine Agonist Drug Market Revenues & Volume, By Injectable, 2021- 2031F |
6.5 Israel Dopamine Agonist Drug Market, By End- Users |
6.5.1 Overview and Analysis |
6.5.2 Israel Dopamine Agonist Drug Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.5.3 Israel Dopamine Agonist Drug Market Revenues & Volume, By Homecare, 2021- 2031F |
6.5.4 Israel Dopamine Agonist Drug Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.5.5 Israel Dopamine Agonist Drug Market Revenues & Volume, By Others, 2021- 2031F |
6.6 Israel Dopamine Agonist Drug Market, By Distribution Channel |
6.6.1 Overview and Analysis |
6.6.2 Israel Dopamine Agonist Drug Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.6.3 Israel Dopamine Agonist Drug Market Revenues & Volume, By Retail Pharmacies, 2021- 2031F |
7 Israel Dopamine Agonist Drug Market Import-Export Trade Statistics |
7.1 Israel Dopamine Agonist Drug Market Export to Major Countries |
7.2 Israel Dopamine Agonist Drug Market Imports from Major Countries |
8 Israel Dopamine Agonist Drug Market Key Performance Indicators |
8.1 Number of clinical trials conducted for dopamine agonist drugs in Israel |
8.2 Adoption rate of dopamine agonist drugs by healthcare professionals in Israel |
8.3 Patient adherence and compliance rates with dopamine agonist drug therapies |
9 Israel Dopamine Agonist Drug Market - Opportunity Assessment |
9.1 Israel Dopamine Agonist Drug Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Israel Dopamine Agonist Drug Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.3 Israel Dopamine Agonist Drug Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.4 Israel Dopamine Agonist Drug Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.5 Israel Dopamine Agonist Drug Market Opportunity Assessment, By End- Users, 2021 & 2031F |
9.6 Israel Dopamine Agonist Drug Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Israel Dopamine Agonist Drug Market - Competitive Landscape |
10.1 Israel Dopamine Agonist Drug Market Revenue Share, By Companies, 2024 |
10.2 Israel Dopamine Agonist Drug Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here